RxDoctor Payments Data

Kristi Taylor

Primary Care · Quincy, FLNPI 1487030987

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 266 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,756in general payments, 2019–2025

Across 266 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$984
  • Boehringer Ingelheim$571
  • Pfizer$557
  • Lilly USA, LLC$458
  • AstraZeneca$369
  • AbbVie$285
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,756100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,756 in reported general payments places this provider in the 95th percentile of 725 primary care providers in Florida.

See all primary care providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin29$36,370
OzempicSemaglutide34$32,049
FarxigaDapagliflozin Propanediol42$32,026
Janumet XrSitagliptin Phos/Metformin Hcl27$29,341
TradjentaLinagliptin17$9,083
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$7,571
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,974
Fluticasone Propionate55$1,279
Mirtazapine28$1,019
Atorvastatin Calcium110$1,014
Albuterol Sulfate HfaAlbuterol Sulfate41$947
Famotidine33$848
Simvastatin82$760
Amlodipine Besylate94$665
Ventolin HfaAlbuterol Sulfate11$565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$571$45,45446 claims
Novo NordiskOzempic$984$32,04934 claims
AstraZenecaFarxiga$369$32,02642 claims
MerckJanumet Xr$147$29,34127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 725 primary care providers in Florida.

Other primary care in Quincy

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →